Serum level of interleukin‐35 as a potential prognostic factor for gastric cancer

Cancer shared this article with you from Inoreader Serum level of interleukin‐35 as a potential prognostic factor for gastric cancer Via Asia-Pacific Journal of Clinical Oncology Abstract Aims Interleukin‐35 (IL‐35), a novel anti‐inflammatory cytokine, has recently been implicated in tumor development, progression, and survival. However, the relationship between serum IL‐35 levels and gastric cancer (GC) is inconclusive. Here, we performed this study to clarify the role of serum level of IL‐35 in GC patients. Methods We enrolled 180 GC patients and 170 healthy controls and used enzyme‐linked immunosorbent assay to detect serum IL‐35 levels. The clinical relevance between IL‐35 and clinical pathology parameters was assessed. Univariate and multivariate logistic regressions were used to determine the feasibility of IL‐35 as a clinical biomarker. Results We observed that serum IL‐35 levels were significantly higher in GC patients (17.559 ± 13.266 pg/mL) than in healthy controls (8.077 ± 3.801 pg/mL, P < .001). High serum IL‐35 levels were significantly associated with clinical stage (P = .048) and Helicobacter pylori (HP) infection (P < .001). The Kaplan‐Meier survival analysis indicated that patients in the high‐IL‐35 group had poor overall survival (OS) and progression‐free survival (PFS) (median OS: 26.0 vs 36.0 months, P < .001; median PFS: 18.0 vs.26.0 months, P = .044). Multivariate analyses demonstrated that serum IL‐35 was an independent prognostic factor for GC (OS: hazard ratio [HR] = 1.031 [95% CI, 1.017‐1.045], P < .001; PFS: HR = 1.029 [95% CI, 1.015‐1.043], P < .001). Conclusions High serum IL‐35 levels are associated with poor disease prognosis in GC patients, and it may be become a new and promising biomarker for prognosis of gastric cancer. View on the web Inoreader. Take back control of your news feed. Follow us on Twitter and Facebook.